QLIFE HOLDING AB, Interim Report Q4, January to December 2023
Looking ahead with new partnersFinancial summary – fourth quarter 2023 · Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is solely from test orders of CRP capsules and Egoo systems. · EBITDA for the period amounted to kSEK –9,466 (-16,843), and net loss kSEK –111,547 (-25,413). · The total cash flow in the fourth quarter amounted to kSEK -6,095 (3,103). · Earnings per share before/after dilution for the quarter amounted to SEK -0,019 (-1.17), calculated on weighted average number of